AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12269263 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (anthracycline-containing regimens)
Number of subjects: 0
Study 12269263 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (general)
Number of subjects: 0
Study 10825855 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Tartar Control Plus Whitening Fluoride Toothpaste
Number of subjects: 122
Study 10825855 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquafresh Whitening Toothpaste with Fluoride
Number of subjects: 122
Study 10825855 — intervention group
Group type: COMPARATOR
Intervention: Crest Regular Fluoride Toothpaste
Number of subjects: 122
Study 7490154 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mmol potassium and 25 mmol (1000 mg) calcium
Number of subjects: 125
Study 7490154 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mmol potassium and 15 mmol (360 mg) magnesium
Number of subjects: 125
Study 7490154 — intervention group
Group type: EXPERIMENTAL
Intervention: calcium and magnesium
Number of subjects: 125
Study 7490154 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 125
Study 2088373 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthrinse
Number of subjects: 78
Study 2088373 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture soft relines
Number of subjects: 78
Study 2088373 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 78
Study 2088373 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic rinse
Number of subjects: 78
Study 2088373 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture relines
Number of subjects: 78
Study 2088373 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic rinse and relines
Number of subjects: 78
Study 752863 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 310
Study 752863 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 310
Study 752863 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 310
Study 752863 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstention
Number of subjects: 310
Study 31858615 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled volatile organic compounds (VOCs) analysis for CRC detection
Number of subjects: 447
Study 31858615 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled volatile organic compounds (VOCs) analysis for advanced adenomas (AAs) detection
Number of subjects: 447
Study 31858615 — intervention group
Group type: EXPERIMENTAL
Intervention: Training models for CRC
Number of subjects: 447
Study 31858615 — intervention group
Group type: EXPERIMENTAL
Intervention: Training models for AAs
Number of subjects: 447
Study 31858615 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind validation for CRC
Number of subjects: 447
Study 31858615 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind validation for AAs
Number of subjects: 447
Study 30502019 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen/hydrocodone 325/5 mg (AH, opioid group)
Number of subjects: 60
Study 30502019 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen/ibuprofen 500/400 mg (AIBU, nonopioid group)
Number of subjects: 60
Study 30502019 — intervention group
Group type: COMPARATOR
Intervention: Control group (AH)
Number of subjects: 60
Study 30502019 — intervention group
Group type: COMPARATOR
Intervention: Control group (AIBU)
Number of subjects: 60
Study 28482350 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer Capacitive Resistive Energy (TCARE) therapy
Number of subjects: 96
Study 28482350 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 96
Study 26081580 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 80
Study 26081580 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 80
Study 26081580 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 80
Study 23583457 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary non‐pharmacological treatment (four sessions)
Number of subjects: 151
Study 23583457 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 min education followed by 3 months waiting time)
Number of subjects: 151
Study 21315787 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 452
Study 21315787 — intervention group
Group type: COMPARATOR
Intervention: Risperidone long-acting injectable (RIS-LAI)
Number of subjects: 452
Study 19154841 — intervention group
Group type: EXPERIMENTAL
Intervention: PROPRIO 5000 dynamic motion analysis score
Number of subjects: 40
Study 19154841 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroCom sensory organization test (SOT)
Number of subjects: 40
Study 17536602 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine functional testing (maximum endurance exercise treadmill testing with nuclear perfusion imaging at 1.5 and 6 months)
Number of subjects: 84
Study 17536602 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine functional testing
Number of subjects: 84
Study 17536602 — intervention group
Group type: COMPARATOR
Intervention: Selective functional testing (only underwent functional testing for a clinical indication)
Number of subjects: 84
Study 11302006 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g isolated soy protein (ISP) daily
Number of subjects: 104
Study 11302006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (caseinate)
Number of subjects: 104
Study 9005609 — intervention group
Group type: EXPERIMENTAL
Intervention: lomir SRO‐5 for 4 weeks
Number of subjects: 20
Study 9005609 — intervention group
Group type: EXPERIMENTAL
Intervention: double dose of lomir for 2 weeks
Number of subjects: 20
Study 1740585 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen incubation
Number of subjects: 11
Study 1740585 — intervention group
Group type: COMPARATOR
Intervention: Buffer incubation
Number of subjects: 11
Study 6723348 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin (500 mg 3-times daily for 3 days)
Number of subjects: 42
Study 6723348 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (500 mg 3-times daily for 5 days)
Number of subjects: 42
Study 6723348 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin
Number of subjects: 42
Study 6723348 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 42
Study 6723348 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin and Erythromycin
Number of subjects: 42
Study 27310418 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT plus healthy lifestyle (CBT-HL)
Number of subjects: 33
Study 27310418 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Depression Only (CBT)
Number of subjects: 33
Study 29983749 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee unloading shoes (ASICS GEL-Melbourne OA)
Number of subjects: 21
Study 25730589 — intervention group
Group type: EXPERIMENTAL
Intervention: Nei-Guan (P6) acupressure wristband applied 30 minutes before anesthesia, removed before leaving recovery room.
Number of subjects: 60
Study 25730589 — intervention group
Group type: COMPARATOR
Intervention: Placebo group received usual nursing care plus a wristband at the non-P6 site.
Number of subjects: 60
Study 25730589 — intervention group
Group type: COMPARATOR
Intervention: Control group received usual care without the wristband.
Number of subjects: 60
Study 24548338 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic pre-conditioning (three 5-min periods of left upper arm ischaemia with 5-min reperfusion each)
Number of subjects: 27
Study 24548338 — intervention group
Group type: COMPARATOR
Intervention: No remote ischaemic pre-conditioning
Number of subjects: 27
Study 22400447 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental dive at 50 meters (6 bar) with nitrogen narcosis
Number of subjects: 22
Study 22400447 — intervention group
Group type: COMPARATOR
Intervention: Control dive at 0 meters (1 bar) without nitrogen narcosis
Number of subjects: 22
Study 21029824 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant (3 mg/kg for 10 minutes, followed by 2 mg/kg 15 minutes later if needed)
Number of subjects: 265
Study 21029824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 21029824 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant (overall population)
Number of subjects: 265
Study 21029824 — intervention group
Group type: COMPARATOR
Intervention: Placebo (overall population)
Number of subjects: 265
Study 18926947 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 PSIL of well differentiated HCC
Number of subjects: 43
Study 18926947 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 PSIL of moderately differentiated HCC
Number of subjects: 43
Study 18926947 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 PSIL of poorly differentiated HCC
Number of subjects: 43
Study 18926947 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 PSIL of hyperplastic nodules
Number of subjects: 43
Study 18926947 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of T2 PSIL among HCC grades
Number of subjects: 43
Study 18926947 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of T2 PSIL between well differentiated HCC and hyperplastic nodules
Number of subjects: 43
Study 18926947 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic post contrast T1 study
Number of subjects: 43
Study 15811480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) 10 mg/d + Simvastatin (SIMVA) 10, 20, 40, or 80 mg/d
Number of subjects: 433
Study 15811480 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + Simvastatin (SIMVA)
Number of subjects: 433
Study 12217993 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultations with practice nurses to discuss health concerns and develop plans for healthier lifestyles
Number of subjects: 1516
Study 12217993 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1516
Study 10756611 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice follow-up
Number of subjects: 296
Study 10756611 — intervention group
Group type: COMPARATOR
Intervention: Hospital outpatient follow-up
Number of subjects: 296
Study 7497867 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 75-g oral glucose tolerance test
Number of subjects: 2520
Study 2034707 — intervention group
Group type: EXPERIMENTAL
Intervention: High voltage pulsed direct current (HVPC)
Number of subjects: 17
Study 2034707 — intervention group
Group type: COMPARATOR
Intervention: Placebo HVPC
Number of subjects: 17
Study 30658845 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000mg acetaminophen (propacetamol)
Number of subjects: 80
Study 30658845 — intervention group
Group type: COMPARATOR
Intervention: 2mcg.kg‐1 fentanyl
Number of subjects: 80
Study 29690786 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based body scan (n = 24)
Number of subjects: 50
Study 29690786 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 26)
Number of subjects: 50
Study 27142328 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (Boostrix(®)) during pregnancy
Number of subjects: 0
Study 27142328 — intervention group
Group type: COMPARATOR
Intervention: No vaccine (control group)
Number of subjects: 0
Study 25517809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin skin test (TST) followed by isoniazid preventive therapy (IPT)
Number of subjects: 100
Study 25517809 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 21802254 — intervention group
Group type: EXPERIMENTAL
Intervention: Piriformis-sparing (PS) approach
Number of subjects: 22
Study 21802254 — intervention group
Group type: COMPARATOR
Intervention: Standard posterior approach
Number of subjects: 22
Study 21802254 — intervention group
Group type: COMPARATOR
Intervention: Both approaches
Number of subjects: 22
Study 19846355 — intervention group
Group type: EXPERIMENTAL
Intervention: EAM800x10 (moxifloxacin 400 mg b.i.d. for 10 days)
Number of subjects: 393
Study 19846355 — intervention group
Group type: EXPERIMENTAL
Intervention: EAM800x7 (moxifloxacin 400 mg b.i.d. for 7 days)
Number of subjects: 393
Study 19846355 — intervention group
Group type: EXPERIMENTAL
Intervention: EAM800x5 (moxifloxacin 400 mg b.i.d. for 5 days)
Number of subjects: 393
Study 19846355 — intervention group
Group type: EXPERIMENTAL
Intervention: EAM400x10 (moxifloxacin 400 mg o.i.d. for 10 days)
Number of subjects: 393
Study 19846355 — intervention group
Group type: EXPERIMENTAL
Intervention: EAM800x10 (retreatment for unsuccessful patients from EAM800x5 and EAM400x10)
Number of subjects: 393
Study 19846355 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line rifabutin-based therapy after EAM800x10 and EAM800x7
Number of subjects: 393
Study 18616895 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective single embryo transfer (SET)
Number of subjects: 0
Study 18616895 — intervention group
Group type: COMPARATOR
Intervention: Double embryo transfer (DET)
Number of subjects: 0
Study 16054474 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0
Study 16054474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12426976 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/125 mg twice daily
Number of subjects: 62
Study 12426976 — intervention group
Group type: COMPARATOR
Intervention: 500 mg/125 mg three times a day
Number of subjects: 62
Study 10323412 — intervention group
Group type: EXPERIMENTAL
Intervention: -47C/-20C allele
Number of subjects: 574
Study 10323412 — intervention group
Group type: COMPARATOR
Intervention: Variant allele frequency
Number of subjects: 574
Study 8520759 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine 2.5 mg
Number of subjects: 6
Study 8520759 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine 5.0 mg
Number of subjects: 6
Study 8520759 — intervention group
Group type: COMPARATOR
Intervention: Nebulized saline (control)
Number of subjects: 6
Study 1836894 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 18
Study 1836894 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 30 mg
Number of subjects: 18
Study 1836894 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg
Number of subjects: 18
Study 1836894 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 30 mg (evening)
Number of subjects: 18
Study 1836894 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg
Number of subjects: 18
Study 1836894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7042363 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 300 mg/day
Number of subjects: 80
Study 7042363 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 600 mg/day
Number of subjects: 80
Study 7042363 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 1500 + diazepam 6 mg/day
Number of subjects: 80
Study 7042363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 28093056 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Navigator Program (PNP)
Number of subjects: 67
Study 28093056 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 67
Study 26459355 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-free e-cigarette
Number of subjects: 20
Study 26459355 — intervention group
Group type: COMPARATOR
Intervention: Traditional cigarette
Number of subjects: 20
Study 23361033 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mix (EUGI)
Number of subjects: 150
Study 23361033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 21341957 — intervention group
Group type: EXPERIMENTAL
Intervention: Online, interactive, sexual risk-reduction intervention
Number of subjects: 560
Study 21341957 — intervention group
Group type: COMPARATOR
Intervention: Wait list null control
Number of subjects: 560
Study 19700189 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured self-etching adhesive with light-guiding attachment and smear layer removal
Number of subjects: 54
Study 19700189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cured self-etching adhesive with light-guiding attachment and smear layer removal
Number of subjects: 54
Study 19700189 — intervention group
Group type: COMPARATOR
Intervention: Light-cured self-etching adhesive
Number of subjects: 54
Study 19700189 — intervention group
Group type: COMPARATOR
Intervention: Dual-cured self-etching adhesive
Number of subjects: 54
Study 17191240 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare Metal Stent (BMS)
Number of subjects: 0
Study 17191240 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-Eluting Stent (SES)
Number of subjects: 0
Study 17191240 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Stent (PES)
Number of subjects: 0
Study 17191240 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Late Loss (MaxLL)
Number of subjects: 0
Study 17191240 — intervention group
Group type: EXPERIMENTAL
Intervention: Average Late Loss (AvgLL)
Number of subjects: 0
Study 15050677 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-model analyses for group-randomized trials (GRTs) with a nested cohort design
Number of subjects: 0
Study 15050677 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustments for fixed and time-varying covariates in mixed-model analyses
Number of subjects: 0
Study 15050677 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations over time in mixed-model analyses
Number of subjects: 0
Study 12236384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to increase pharmacists' involvement in caring for customers
Number of subjects: 36
Study 12236384 — intervention group
Group type: EXPERIMENTAL
Intervention: Conducting research consistent with corporate goals
Number of subjects: 36
Study 12236384 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility in research design
Number of subjects: 36
Study 9851956 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet (10 mEq/d)
Number of subjects: 8
Study 9851956 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (400 mEq/d)
Number of subjects: 8
Study 9851956 — intervention group
Group type: COMPARATOR
Intervention: Intravenous deuterated verapamil
Number of subjects: 8
Study 8209272 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (MIP protocol: mitomycin 6 mg/m2 day I, ifosfamide 1.5 g/m2 days 1 to 3, cisplatin 30 mg/m2 days I to 3, mesna 1,200 mg/m2 days 1 to 3) followed by surgery and additional chemotherapy for responders.
Number of subjects: 150
Study 8209272 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (control group).
Number of subjects: 150
Study 2606121 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of 0.3 to 0.5 mg ethinyloestradiol (EE) daily
Number of subjects: 82
Study 2606121 — intervention group
Group type: COMPARATOR
Intervention: Low dose of 0.1 mg ethinyloestradiol (EE) daily
Number of subjects: 82
Study 31561653 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 paravertebral block (T2 PVB)
Number of subjects: 15
Study 31561653 — intervention group
Group type: COMPARATOR
Intervention: Stellate ganglion block (SGB)
Number of subjects: 15
Study 28437161 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab 8 mg/kg → 6 mg/kg once every 3 weeks plus capecitabine 1,250 mg/m2 twice a day (2 weeks on, 1 week off, every 3 weeks)
Number of subjects: 452
Study 28437161 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab 840 mg → 420 mg once every 3 weeks plus trastuzumab at the same dose and schedule as arm A plus capecitabine 1,000 mg/m2 on the same schedule as arm A
Number of subjects: 452
Study 25447621 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry (FEV1)
Number of subjects: 1969
Study 25447621 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 1969
Study 25447621 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent emphysema on CT
Number of subjects: 1969
Study 25447621 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating curve improvement
Number of subjects: 1969
Study 23022704 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg in 100 ml of isotonic saline, intravenously
Number of subjects: 70
Study 23022704 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 ml of isotonic saline)
Number of subjects: 70
Study 21940599 — intervention group
Group type: EXPERIMENTAL
Intervention: LIS participants
Number of subjects: 108
Study 21940599 — intervention group
Group type: EXPERIMENTAL
Intervention: LIR participants
Number of subjects: 108
Study 21940599 — intervention group
Group type: EXPERIMENTAL
Intervention: OIR participants
Number of subjects: 108
Study 21940599 — intervention group
Group type: COMPARATOR
Intervention: LIS vs OIR
Number of subjects: 108
Study 21940599 — intervention group
Group type: COMPARATOR
Intervention: LIS vs LIR
Number of subjects: 108
Study 21940599 — intervention group
Group type: COMPARATOR
Intervention: LIR vs OIR
Number of subjects: 108
Study 18680629 — intervention group
Group type: EXPERIMENTAL
Intervention: High SFA (HSFA) diet
Number of subjects: 0
Study 18680629 — intervention group
Group type: EXPERIMENTAL
Intervention: High MUFA (HMUFA) diet
Number of subjects: 0
Study 18680629 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat (LF) diet
Number of subjects: 0
Study 18680629 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat with EPA and DHA supplementation (LFn-3) diet
Number of subjects: 0
Study 16981920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein ablation for atrial fibrillation (AF)
Number of subjects: 105
Study 15213591 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 416
Study 15213591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 11504899 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride releasing elastomeric modules
Number of subjects: 21
Study 11504899 — intervention group
Group type: COMPARATOR
Intervention: Conventional modules (Control)
Number of subjects: 21
Study 9693890 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy with a transparent cap
Number of subjects: 24
Study 9693890 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy without a transparent cap
Number of subjects: 24
Study 7847611 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g ethanol/kg body weight
Number of subjects: 9